#USA #Bethlehem #Bioreactor #ABEC #ATB™-2100

ABEC Launches ATB™-2100 Advanced Therapy Bioreactor

In a significant step forward for biopharmaceutical manufacturing, ABEC has unveiled its latest innovation, the ATB™-2100 Advanced Therapy Bioreactor. This state-of-the-art platform is specifically engineered to meet the increasing demands of the cell and gene therapy sectors. With a focus on scalability, reproducibility, and automation, the ATB™-2100 is poised to transform how therapies are produced from initial development stages through to commercial availability.

The ATB™-2100 represents a shift in advanced therapy processing by integrating enhanced process control within a closed and fully automated system. Designed to support complex applications common in cell and gene therapies, this platform has demonstrated success in cultivating T-cells, induced pluripotent stem cells (iPSCs), and mesenchymal stem cells (MSCs), among other innovative modalities.

At the heart of this technology lies ABEC's proprietary hollow-fiber perfusion membranes. These membranes continuously supply essential nutrients and gases while simultaneously removing metabolic waste from the culture environment. This paradigm mimics the human circulatory system, creating an optimal low-shear environment for cell growth that minimizes stress and bolsters both cell density and viability.

One of the standout features of the ATB™-2100 is its ability to maintain a consistent membrane surface-area-to-volume ratio across various bioreactor volumes, ranging from 200mL to 10L. This consistency allows seamless transition of process conditions from early-stage research and development to large-scale commercial production, effectively shortening development timelines and reducing risks associated with technology transfer.

Scott Pickering, ABEC's CEO, highlighted the platform's importance in addressing the manufacturing challenges faced by cell and gene therapies. “These therapies are often hindered by scalability issues, high costs, and slow pathways to commercialization. The ATB™-2100 addresses these challenges head-on and signifies another pivotal advancement in the industry.”

ABEC's commitment to enhancing the efficiency and success of manufacturing processes is evident in the ATB™-2100. With over fifty years of experience in engineered solutions for biopharmaceutical manufacturing, ABEC steps forward to offer innovative solutions that enable faster time-to-market and reduced overall production costs, paving the way for the next generation of life-changing therapies.

For more detailed information about the ATB™-2100 Advanced Therapy Bioreactor, please visit ABEC's official website or reach out through their contact
info email.

ABEC is recognized globally for its pioneering work in providing engineered solutions that empower biopharmaceutical manufacturing, standing at the forefront of innovation in this critical field.